STRENGTHS AND LIMITATIONS OF THIS STUDY
-
A rigorous search of published and unpublished data will be conducted.
-
We will attempt to use the risk assessment tool from the Cochrane Handbook V.5.1.0 and assess the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach.
-
Due to the differences in the types of virtual reality (VR) devices used and the variations in intervention duration, the combined effect estimates may be heterogeneous.
-
The limitation is that there may be few studies on VR relieving anxiety and pain during colonoscopy, and subgroup analysis may not be possible.
Introduction
Colonoscopy is a relatively safe and effective method for visually examining the entire large intestine. However, it is often perceived by patients as a painful and uncomfortable procedure. Studies have shown that patients commonly experience moderate levels of anxiety during colonoscopy.1–3 In addition, the physical sensations associated with colonoscopy, such as the reflex spasms triggered by stimulation of the colon to improve visualisation, as well as the acute distension caused by the buildup of gas, can contribute to the pain and discomfort experienced by patients during and after the procedure.1
The research shows that there is a direct relationship between pain and anxiety, and they aggravate the severity of each other.4 Sedation is the preferred method for reducing pain, anxiety and other discomfort in patients undergoing colonoscopy.5 However, the administration of sedative agents during colonoscopic procedures is inherently associated with adverse effects, primarily due to the suppression of pulmonary and cardiovascular functions.6 7 Furthermore, sedation during colonoscopy increases the risk of postprocedural pneumonia in elderly patients,8 and deeper levels of sedation even increase the risk of patients developing the procedure-related complication of perforation.9 Finally, the need to closely monitor patients during and after sedation for colonoscopy procedures poses both logistical challenges and financial burdens.10
Virtual reality (VR) is an innovative technology that enables the generation of immersive and interactive simulated environments. These VR environments closely mimic the physical world, allowing users to freely explore and engage with the virtual surroundings.11 Its application in medicine has shown success in alleviating pain and anxiety during various procedures, such as wound debridement,12 13 painful and invasive procedures (eg, injection applications),14 15 lumbar puncture,16 orthopaedic surgery17 and cystoscopy.17 Given its mechanism of engaging visual and auditory senses, VR may therefore be a promising intervention for alleviating pain and anxiety and stabilising vital signs (eg, blood pressure, heart rate and peripheral oxygen saturation) in patients undergoing colonoscopy.
Previous meta-analyses found that music intervention during colonoscopy reduced procedure time and sedation requirements but did not significantly impact patient-reported pain scores.18–20 Similarly, research on visual distraction alone has reported reduced patient pain, increased satisfaction and a greater willingness among patients to undergo a repeat surgery.21 Although music intervention and visual distraction have been associated with anxiety and discomfort related to colonoscopy, previous studies have not considered the combined effects of both.22 23 Recently, it has also been reported that audiovisual distraction can likewise effectively reduce the pain experience of patients undergoing colonoscopy. VR offers a potent form of audiovisual distraction, but its clinical efficacy and safety in this context have not been systematically summarised. In order to clarify the effects of audiovisual intervention using VR during colonoscopy, we conducted a systematic review and meta-analysis of relevant randomised controlled trials (RCTs).
Methods
Eligibility criteria
Type of studies
We will only include RCTs that directly compare an intervention group, where participants received VR devices during their colonoscopy procedure, against a control group, where participants underwent the routine colonoscopy protocol.
Type of population
All patients were ≥18 years of age and had no psychiatric disorders, such as anxiety disorders.
Type of intervention
The aim of the RCTs included in this review should be to evaluate the effectiveness of VR in alleviating anxiety and discomfort in patients undergoing colonoscopy. For clarity, we define VR as a technology that creates immersive and interactive environments, incorporating dynamic visual and auditory elements.
Outcome measures
To be included in this study, the eligible studies must have assessed and reported on the following key outcome indicators, which were evaluated using reliable and validated measurement tools:
-
Pain score: The studies should have evaluated the patient’s pain level during the colonoscopy procedure, using a validated pain assessment tool such as the Visual Analogue Scale or Numerical Rating Scale.
-
Anxiety score: The studies should have assessed the patient’s level of anxiety, either state anxiety (related to the specific procedure) or trait anxiety (general anxiety), using a reliable measure such as the Spielberger State-Trait Anxiety Inventory .
Exclusion criteria
-
Only VR technology with audiovisual distraction was used.
-
Excluded case studies, reviews, editorials, duplicates, incomplete studies and those lacking analytical numerical data.
-
Excluded studies without a control group or insufficient information regarding our selected outcomes.
Search strategy
Two independent reviewers performed an extensive search across four electronic databases: PubMed, EMBASE, Web of Science and Cochrane Library Database, covering the period from their inception until August 2024. To supplement the electronic database search, grey literature will be identified via resources such as GreyNet International, OpenGrey and Google Scholar, with further expansion achieved through manual searches of the reference lists of included studies. The search strategies for each database are detailed in the online supplemental appendix 1.
Supplemental material
Two reviewers independently screened the records of titles and abstracts retrieved from electronic searches to identify potentially relevant studies. They then assessed and screened the full texts based on the inclusion criteria. Any disputes were resolved through consultation with a third researcher. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram will be used to illustrate the study selection process (figure 1).24
Data management
Two researchers independently used EndNote X9 (Clarivate Analytics, Philadelphia, Pennsylvania, USA) to identify and eliminate duplicates.
Data extraction
Two reviewers will independently extract data on specifically developed forms from the included studies for the following items:
-
Participants: age, sex, number, country, pain score, previous abdominal surgeries, prior colonoscopy and anxiety score.
-
Interventions: details of the VR system (content and delivery device) and duration of use.
-
Comparators: the specific type of comparator (pharmacological sedation).
-
Outcomes: primary outcomes of pain and anxiety levels (including the assessment tools used) and any reported VR-related adverse events.
-
Study design: arms, purpose, inclusion and exclusion criteria characteristics, sample size, items relevant to risk of bias and quality ratings.
-
Others: author and year.
Any discrepancies or disagreements during data extraction will be resolved through discussion to reach a consensus.
Risk of bias and clinical relevance
We will assess the risk of bias in included studies using the Cochrane Handbook V.5.1.0 risk of bias tool. This assessment will focus on seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective reporting and other potential biases. Each domain will be assigned a risk level of low, high or uncertain. Disagreements will be resolved through discussion among the review team or consultation with additional reviewers.
Measures of treatment effect
We will use RevMan V.5.4 software to calculate outcome data. Continuous data will be reported as weighted mean differences and standardised mean differences, while dichotomous data will be expressed as risk ratios and 95% CIs.
Additions of missing data
To address missing data, we will try to contact the original study authors. If we are unable to obtain the necessary information after two attempts, studies with insufficient data will be excluded from the analysis.
Assessment of heterogeneity
We will assess heterogeneity using χ2 tests and I2 values, following the guidelines outlined in the Cochrane Handbook. 25 If I2<50%, indicating acceptable heterogeneity, a fixed-effects model will be used for analysis. If I2>50%, indicating substantial heterogeneity, a random-effects model will be employed. Studies with effect sizes that cannot be combined will undergo descriptive analysis only. A narrative analysis will be conducted when quantitative synthesis is not appropriate.
Subgroup analysis
Subgroup analysis will be conducted when data permits. These subgroups may be defined based on factors such as participant age and gender, the type and content of the VR device, the duration of VR use and the type and dosage of sedatives administered.
Sensitivity analysis
We will use a study-by-study exclusion method for individual studies, followed by sensitivity analyses on the remaining studies. Studies with a high risk of bias will be excluded to enhance the accuracy and reliability of our findings.
Reporting bias analysis
We will assess publication bias by examining the symmetry of a funnel plot. We will also evaluate publication bias by performing the Begg’s and Egger’s tests.
Confidence in cumulative evidence
We will use the Grading of Recommendations Assessment, Development and Evaluation criteria (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of evidence, classifying it as high, moderate, low or very low. The methods and recommendations outlined in the Cochrane Handbook will be applied throughout this process.26
Patient and public involvement
There is no patient or public involvement in this study.
Ethics and dissemination
This systematic review and meta-analysis did not require ethics approval. The findings will be disseminated through publication in a peer-reviewed journal.
Amendments
The information will be described in the final report and if the protocol is modified.
Discussion
Colonoscopy is considered the gold standard for diagnosing colorectal cancer because it allows for the timely detection and intervention of suspicious intestinal tissue, preventing the progression of the disease.27 However, the colonoscopy procedure can cause pain, anxiety and other discomfort in patients, which can affect their cooperation during the procedure and their willingness to undergo repeat colonoscopies.28 29 Although sedative drugs can alleviate anxiety and pain symptoms, the procedure-related side effects deter some patients from taking the medication.22 VR combines computer-generated visual and auditory signals to create an immersive, simulated experience that mimics the physical world.30 31 Immersive VR can have an analgesic effect by distracting patients and has also been used to reduce pain during invasive procedures in the medical field.32 33
While there are some relevant clinical studies, the effectiveness of VR in alleviating patient discomfort and anxiety during colonoscopy remains unclear. A systematic assessment is therefore warranted to synthesise the current evidence and clarify the effectiveness of VR in this clinical context.
The conclusions of this study should be considered in light of several limitations. First, potential heterogeneity is a significant issue, originating from variations in participant demographics (such as age and gender), the type and content of the VR device and the duration of VR use. Second, the evidence base is constrained by a paucity of clinical studies, small sample sizes and a lack of detailed subgroup analyses. Third, in studies where VR was compared against sedation, the variations in the class and dosage of sedatives are a likely confounding factor that could introduce significant heterogeneity. To address these sources of variability, we will undertake subgroup analyses, when possible, to examine the impact of demographic factors, VR equipment, content, duration and the administration of sedatives.
Ethics statements
Patient consent for publication
This post was originally published on https://bmjopen.bmj.com
